IJSTR

International Journal of Scientific & Technology Research

IJSTR@Facebook IJSTR@Twitter IJSTR@Linkedin
Home About Us Scope Editorial Board Blog/Latest News Contact Us
CALL FOR PAPERS
AUTHORS
DOWNLOADS
CONTACT
QR CODE
IJSTR-QR Code

IJSTR >> Volume 4 - Issue 8, August 2015 Edition



International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616



Lipids And Hscrp As Markers Of Coronary Heart Disease Risk In HIV Infected Adults

[Full Text]

 

AUTHOR(S)

Danai Tavonga Zhou, Vitaris Kodogo, Munyaradzi Dzafitita, Olav Řktedalen, Rudo Muswe, Babill Stray-Pedersen

 

KEYWORDS

Index Terms: antiretroviral therapy, cardiovascular disease, HIV, hsCRP, inflammation, lipid,

 

ABSTRACT

Abstract: Life-expectancy among HIV-infected patients has risen due to use of antiretroviral drugs. However there are new concerns as accompanying metabolic and morphologic changes predispose HIV-infected individuals to cardiovascular disease. Progression of cardiovascular disease is a slow process marked by both changes in lipid levels and low grade systemic inflammation, assessed using highly sensitive C-reactive protein (hs-CRP). The aim of the study was to evaluate the risk of cardiovascular disease in HIV-infected patients using lipids and hs-CRP levels. Serum and plasma samples were collected from HIV-infected adults who were antiretroviral therapy-experienced (n=87) or antiretroviral therapy-naďve (n=10). Samples were analysed using Siemens® Dimension Xpand analyser. Mean hs-CRP for all participants suggested that they had some risk of cardiovascular disease in spite of antiretroviral therapy history. Of all 97 participants, 57.7% had elevated hs-CRP levels (>3mg/dL) suggesting high risk, 26.8% had levels between 1 and 3mg/dL (average risk) and 34% had levels below 1mg/dL (low risk). Lipid levels were normal in all participants and there was no correlation between hs-CRP and lipid levels. There was no significant difference in hs-CRP levels by sex, age and antiretroviral therapy history. Elevated hs-CRP levels of participants suggest that HIV-infected patients may be at risk of cardiovascular disease through low-grade inflammation.

 

REFERENCES

[1] Friis-Moller N., Roiss P, Sabin C. A., Combination of Antiretroviral Therapy and the Risk of Myocardial Infarction, 1993-2003, New England Journal of Medicine; 349, 2003

[2] Ridker P.M., High-sensitivity C - reactive protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. Circulation, 103:1813–1818, 2002

[3] D’Arminio, Sabin CA., Phillips AN., Cardiovascular and Cerebrovascular Events in HIV-infected persons, AIDS 18:1811-7, 2004

[4] Grinspoon S, Carr A. Cardiovascular Risk and Body-fat Abnormalities in HIV-Infected Adults, New England Journal of Medicine 16: 42-44, 2005

[5] Friis-Moller N., Webber R., Reiss P et al. Cardiovascular Disease Risk Factors in HIV Patients on Antiretroviral Therapy. AIDS 17(8):1179-93, 2003

[6] Libby P., Ridker P. M. et al. 1999. Novel markers of inflammation: Theory vs practice. Circulation 100: 1140-1150

[7] Pearson T. A. Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention., Markers of inflammation and cardiovascular diseases: Application to Clinical and Public Health. Circulation 107: 499-511, 2003

[8] Tracy R P., Inflammation in Cardiovascular Disease, Circulation; 97:2000-2002, 1998.

[9] Ross R., Atherosclerosis an Inflammatory Disease, New England Journal of Medicine 340: 115-126, 1999

[10] Koenig W., Sund M., Frohlich M., Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB, C-reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-aged Men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease), Augsburg Cohort Study, 1984 to 1992, Circulation, 99(2): 237–242, 1999

[11] Roberts W.L., Moulton L., and Law T.C., Evaluation of Nine Automated High-Sensitivity C-reactive Protein Methods: Implications for Clinical and Epidemiological Applications: Part 2. Clinical Chemistry.47: 418–425, 2001

[12] Kaplan R.C., Kingsley L.A., Sharett A.R. Li X, Lazar J, Tien PC, Mack WJ, Cohen MH, Jacobson L, Gange SJ., Ten year predicted coronary heart disease risk in HIV-infected men and women. Clinical Infectious Disease, 45(8): 1074-81, 2007

[13] Ridker P. M., Inflammation in Atherothrombosis: How to Use hs-CRP in Clinical Practice. The American Heart Hospital Journal, 2(4 Suppl 1):4-9, 2004

[14] De Luca A., de Gaetano Donati K., Colafigli M, Cozzi-Lepri A, De Curtis A, Gori A, Sighinolfi L, Giacometti A, Capobianchi MR, Avino AD, Iacoviello L, Cauda R, Monforte ADA, The Association of hs-CRP and Other Biomarkers With Cardiovascular Disease in Patient Treated for HIV: a Nested Case-Control Study, BMC Infectious disease, 13:414, 2013

[15] Triant VAM, Meigs JBM, Grinspoon SKM. Association Between C-reactive Protein and HIV Infection with Acute Myocardial Infarction. Journal of AIDS, 51, 268-273, 2009

[16] Lwedaba L., Tavel J.A., Khabo P., Maja P., Qin J., Sangweni P, Liu X., Follmann D., Metcalf J.A., Orsega S., for Project Phidisa Biomarkers, Pre-Art Levels of Inflammation and Coagulation are Strong Predictors of Death in South African cohort with Advanced HIV Disease, Plos One DOI 10.1371: 0024243, 2012

[17] Strategies for Management of Antiretroviral Therapy/INISIGHT, D:A:D Study Groups, Use of Nucleoside Reverse Transcriptase Inhibitors and Risk of Myocardial Infarction in HIV-Infected Patients, Journal of AIDS F17-F24, 2008

[18] Kristerffersen U.S., Koefed K., Benfield T., Kjaer A., Kronberg S., Lebech A.M., Changes in Biomarkers of Cardiovascular Risk After a Switch to Abacavir in HIV-Infected Individuals Receiving cART, HIV Medication 10, 627-633, 2009

[19] Ridker P. M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. Journal of the American College of Cardiology 2007 May 29; 49(21):2129-38, 2007

[20] Boger S. M. et al. hs-CRP, BMI, and Serum Lipid in HIV-Infected Persons: A Longitudinal Study. Journal of AIDS Volume 52 Issue 4 p480-487, 2009

[21] http://www.healthcare.siemens.com/clinical-specialities/ cardiovascular/laboratory-expert/education/content/high-sensitivity-c-reactive-protein-hscrp-assay

[22] Shikuma C, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, KuritzkesDR, Glesby MJ, and the AIDS Clinical Trials Group A5095 Study Team, Change in Hs-CRP levels following Efavirenz-based ARVs in HIV-Infected individuals, AIDS Research and Human Retroviruses 27(5): 461-468, 2011

[23] Bergersen. (2006). Cardiovascular risk in patients with HIV infection: Impact of Antiretroviral Therapy. Drugs 2006: 16(15) 1971-87.

[24] Judith A Aberg, MD. 2003. Cardiovascular risk among HIV-positive patients on ART. Journal of IAPAC, vol 2, sup 2

[25] Takara L Stanley, Steven K Grinspoon, Body composition and Metabolic Changes in HIV-infected. Journal of Infectious Disease 2012; 205 (suppl 3) S85-S390, 2012

[26] Savčs M., Chęne G., Ducimetičre P, Leport C, Le Moal G, Amouyel P, Arveiler D, Ruidavets J-B, Reynes J, Bingham A, Raffi F for the French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population , Clin Infect Dis. (2003) 37 (2): 292-298. doi: 10.1086/375844

[27] Arnett D.K., Falutz J.M., Grunfeld C., Haffner S.M., Working Group I., Contribution of Metabolic and Athropometric Abnormalities to Cardiovascular Disease Risk Factors, Circulation: 118:e20-8, 2008

[28] Pao V., Lee G. A., Sunfield C., HIV Therapy, Metabolic Syndrome and Cardiovascular Disease, Current Atherosclerosis Report, 10(1):61-70, 2008

[29] Saad Al-Fawaeir, Mohammad Basim Abu Zaid, Serum levels of high-sensitivity C-reactive protein (hs-CRP) in Helicobacter pylori infected patients, J Invest Biochem, 2(1): 32-36, 2013

[30] Grützmeier S, Sandström E, C Reactive Protein Levels in HIV Complicated by Opportunistic Infections and Infections with Common Bacterial Pathogens, Scand J Infect Dis, 31(3):229-34, 1999

[31] Arnett D.K., Falutz J.M., Grunfeld C., Haffner S.M., Working Group I., Contribution of Metabolic and Athropometric Abnormalities to Cardiovascular Disease Risk Factors, Circulation: 118:e20-8, 2008

[32] Hidigan C., Borgonha S., Rabe J., Young V., Grinspoon S. Increased Rates of Lipolysis among HIV-Infected Men Receiving HAART. Metabolism 51, 1143-1147, 2002

[33] Sabin C.A., Worm S.W., Weber R., Reiss P., Friis-Moller N., Phillips A.N., D’Arminio Monforte A, for D:A:D Study Group, Use of Nucleoside Reverse Transcriptase Inhibitors and Risk of Myocardial Infarction HIV-Infected patients Enrolled in the D:A:D Study: a Multi-cohort Collaboration. Lancet: 371:1417-26, 2008

[34] Zhou DT, Kodogo V, Chokuona K, Gomo E, Oktedalen O, Stray-Pedersen B, Dyslipidaemia and Cardiovascular Disease Risk Profiles of Patients Attending an HIV Treatment Clinic in Harare, Zimbabwe, HIV/AIDS-Research and Palliative Care, In print